Decreasing Need for Liver Transplants for Hepatitis B Patients.
Each year approximately 6,000 liver transplants are performed in the US; about 4% of recipients have hepatitis B. Since 1996, four oral antiviral medications have been approved by the Food and Drug Administration for treatment of hepatitis B: lamivudine, adefovir dipivoxil, entecavir and telbivudine. "While none of the treatments for hepatitis B 'cure' the disease, medications can stop or reverse its progression," said Ray Kim, MD, a Mayo Clinic hepatologist and lead author of the study, in a University press release. "With the widespread application of the antiviral medications in the past 10 years, physicians have anecdotally noticed that fewer hepatitis B patients seem to need liver transplants."
Dr. Kim's team analyzed nationwide data on patients with hepatitis B and C who were registered with the Organ Procurement and Transplantation Network for liver transplants between 1994 and 2006. They found a rapid increase in the number of liver transplant registrants with hepatitis B and hepatitis C in the 1990s. However, the number of registrants with hepatitis B peaked in 2000 at 586 and then declined by 30 percent over the next six years to 409 in 2006. Link: www.medicalnewstoday.com/articles/87586.php. (12/05/07)
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 1, 2008|
|Previous Article:||Donor Alcohol Use May Fuel Lung Transplant Rejections.|
|Next Article:||Longest-living Artificial Heart Recipient Dies in England.|